List of bibliographic references
Number of relevant bibliographic references: 5.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 2 | Adult |
| 2 | Female |
| 2 | Humans |
| 2 | Male |
| 2 | Prognosis |
| 1 | Adolescent |
| 1 | Anemia, Aplastic (epidemiology) |
| 1 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 1 | Antigens, CD (metabolism) |
| 1 | Antineoplastic agent |
| 1 | Cause of Death |
| 1 | Chronic |
| 1 | Combined Modality Therapy |
| 1 | Comparative study |
| 1 | Erythrocyte Transfusion |
| 1 | Europe |
| 1 | Flow Cytometry (standards) |
| 1 | Follow-Up Studies |
| 1 | France |
| 1 | Hemoglobinuria, Paroxysmal (classification) |
| 1 | Hemoglobinuria, Paroxysmal (mortality) |
| 1 | Hemoglobinuria, Paroxysmal (therapy) |
| 1 | High-Throughput Nucleotide Sequencing (methods) |
| 1 | Immunophenotyping |
| 1 | Incidence |
| 1 | Leukemia |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (pathology) |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (therapy) |
| 1 | Medicine |
| 1 | Middle Aged |
| 1 | Multivariate Analysis |
| 1 | Neoplasm Staging |
| 1 | Neoplasm, Residual (diagnosis) |
| 1 | Neoplasm, Residual (genetics) |
| 1 | Neoplasm, Residual (metabolism) |
| 1 | Ofatumumab |
| 1 | Registries |
| 1 | Retrospective Studies |
| 1 | Risk Factors |
| 1 | Survival Analysis |
| 1 | Thrombosis (epidemiology) |
| 1 | Treatment |
| 1 | Young Adult |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/UK/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "P. Hillmen"
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i \
-Sk "P. Hillmen" \
| HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= UK
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= P. Hillmen
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
